Liver Diseases
36 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Narrower: Acute-On-Chronic Liver Failure 1, Fatty Liver 21, Hepatitis 2, Hepatitis, Alcoholic 1, Liver Cirrhosis 5, Liver Cirrhosis, Biliary 2, Liver Diseases, Alcoholic 2, Liver Failure 5, Non-alcoholic Fatty Liver Disease 16
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Atezolizumab for fatty liver | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Baclofen for liver diseases, alcoholic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Berberine ursodeoxycholate for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Bevacizumab + atezolizumab for fatty liver | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cannabidiol for liver cirrhosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Chemically induced pluripotent stem cells biological Artificial Liver for liver failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DR10624 Injection for non-alcoholic fatty liver disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ECC0509 for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ECC0509 + ECC4703 for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ECC4703 for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Efruxifermin for non-alcoholic fatty liver disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EGEN-5784 (genetically engineered porcine liver) + metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx) for acute-on-chronic liver failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for non-alcoholic fatty liver disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for fatty liver | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for liver cirrhosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for liver failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ex vivo perfusion of six-gene-edited porcine liver + Multi-drug immunosuppressive therapy for liver failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Faecal microbiota transplantation for hepatitis, alcoholic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Faecal microbiota transplantation for liver cirrhosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fenofibrate for liver cirrhosis, biliary | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fenofibrate in Combination With Ursodeoxycholic Acid for liver cirrhosis, biliary | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Food Security Screening & Referral Program for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HepaCure for hepatitis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HepaCure for liver failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HSK31679 for non-alcoholic fatty liver disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HU6 for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| miRNA Biomarker-Guided Immunosuppression Minimization for liver diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Obeticholic acid for fatty liver | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pegargiminase for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for non-alcoholic fatty liver disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for non-alcoholic fatty liver disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| SNP-610 for non-alcoholic fatty liver disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Standard Soy Milk for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Survodutide for liver diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Survodutide for non-alcoholic fatty liver disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Very-low calorie diet for fatty liver | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.